62nd ASH Annual Meeting and Exposition: 904. Outcomes Research

Oral and Poster Abstracts
Poster

Adult, Anemias, autoimmune disorders, Biological, Bleeding Disorders, Coronaviruses, Hemophilia, SARS-CoV-2/COVID-19, sickle cell disease, viral, Bleeding and Clotting, Diseases, Elderly, Therapies, Adverse Events, Genetic Disorders, Biological Processes, Hemoglobinopathies, gene therapy, Immune Disorders, Infectious Diseases, Plasma Cell Disorders, thrombocythemia, Lymphoid Malignancies, Study Population, Clinically relevant, Myeloid Malignancies, Proliferative disorders, Quality Improvement , molecular interactions

1622

Thrombotic Events and Mortality Risk in Patients Newly Diagnosed with Intermediate- to High-Risk Essential Thrombocythemia in the United States

Naveen Pemmaraju, MD¹, Aaron T. Gerds, MD, MS², Jingbo Yu, MD, PhD³, Shreekant Parasuraman, BPharm, PhD³^*, Anne Shah⁴^*, Ann Xi, PharmD⁴^*, Shambhavi Kumar, MS⁴^*, Robyn M. Scherber, MD³ and Srdan Verstovsek, MD, PhD¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
³Incyte Corporation, Wilmington, DE
⁴Avalere Health, Washington, DC

1623

Patient Preferences for Hemophilia a Treatments: A Discrete Choice Experiment

Shawn X. Sun¹^*, Jing Zhao²^*, Hongbo Yang, PhD³^* and Eric Wu²

¹Takeda Pharmaceutical Company Ltd, Cambridge, MA
²Analysis Group, Inc., Boston, MA
³Analysis Group Inc., Boston, MA

1624

Outcomes in Vaso-Occlusive Crisis Treatment in the Emergency Department Vs. Acute Care Observation Center

Renee Cheng, MD¹, Avani Singh, MD², Xu Zhang, PhD²^*, Priyanka Nasa³^*, Jin Han⁴^*, Doris Alfaro⁵^*, Laura Kavoliunaite⁶^*, Chika Nwachukwu, CNP⁷^*, Karen Woodard⁷^*, Robert E. Molokie, MD^8,9, Victor R. Gordeuk, MD² and Michel Gowhari, DO¹⁰

¹Department of Medicine, University of Illinois at Chicago College of Medicine, Chicago, IL
²Department of Medicine, University of Illinois at Chicago, Chicago, IL
³Department of Quality Performance and Improvement, University of Illinois at Chicago, Chicago
⁴Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL
⁵Department of Quality Management, University of Illinois at Chicago, Chicago, IL
⁶Division of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
⁷Division of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL
⁸Jesse Brown VA Medical Center, Chicago, IL
⁹Department of Medicine, Division of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL
¹⁰Division of Hematology/Oncology, University of Illinois at Chicago College of Medicine, Chicago, IL

1625

Inpatient Inherited Thrombophilia Testing at an Academic Health Center: High Cost, Low Value

Ruben Rhoades, MD

Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA

1626

Outcomes of Hydroxyurea Dose Adjustment Via Telehealth

Sarah Shaner¹^*, Lee M Hilliard, MD², Thomas H. Howard, MD², Brandi Pernell, DNP²^*, Smita Bhatia, MD, MPH³ and Jeffrey D. Lebensburger, DO⁴

¹University of Alabama School of Medicine, Birmingham, AL
²Division of Pediatric Hematology Oncology, University of Alabama at Birmingham School of Medicine, Birmingham, AL
³Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL
⁴Division of Pediatric Hematology Oncology, University of Alabama At Birmingham, Birmingham, AL

1627

Mortality Among Veterans with a Diagnosis of Pyruvate Kinase (PK) Deficiency: A Real-World Study Using US Veterans Health Administration Data

Erin Zagadailov, PharmD¹^*, Audra Boscoe, PhD¹^*, Viviana Garcia-Horton, PhD²^*, Sherry Shi, MSc³^*, Shuqian Liu, MD⁴^*, Lizheng Shi, PhD⁴^* and Dendy Macaulay, PhD²^*

¹Agios Pharmaceuticals, Inc., Cambridge, MA
²Analysis Group, Inc., New York, NY
³Analysis Group, Inc., Montréal, QC, Canada
⁴School of Public Health & Tropical Medicine, Tulane University, New Orleans, LA

1628

Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)

Blake T. Langlais, MS¹^*, Heidi E. Kosiorek, MS¹^*, Gina L. Mazza, PhD¹^*, Carolyn Mead-Harvey, MS¹^*, Richard Butterfield III¹^*, Jeanne M. Palmer, Md², Ruben Mesa, MD³ and Amylou C. Dueck, PhD¹

¹Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ
²Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ
³Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX

1629

Bleeding Outcomes of Gastrointestinal Cancer Patients Treated with Direct Oral Anticoagulants Vs. Low Molecular Weight Heparin

Dana E Angelini, MD¹, Doaa Attia, MD²^*, Wei Wei, MS³^*, Mailey L Wilks, DNP, MSN, APRN²^*, Barbara Tripp, APRN, CNS²^*, Christopher D'Andrea, PA-C²^*, Keith R. McCrae, MD² and Alok A Khorana, MD²

¹Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Avon Lake, OH
²Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
³Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

1630

A Patient-Centric Approach to Improve the Understanding of Sickle Cell Disease Using Real-World Data

E. Leila Jerome Clay, MD¹, Miranda Bailey²^*, Dan Drozd, MD, MSc³^*, Jincy Paulose, M.D.²^*, Nicholas Ramscar, MBBS⁴^*, Kieran Mace, PhD³^* and David Wormser, PhD, MSc, MPhil⁴^*

¹Johns Hopkins University, Johns Hopkins All Children’s Hospital, St Petersburg, FL
²US Oncology Medical, Novartis Pharmaceuticals Corporation, East Hanover, NJ
³PicnicHealth, San Francisco, CA
⁴Novartis Pharma AG, Basel, Switzerland

1631

Medically Attended Anxiety or Depression Is Increased Among Newly Diagnosed Patients with Cold Agglutinin Disease (CAD)

Parija Patel¹^*, Xiaohui Jiang²^*, Gina Nicholson²^*, Cara Frankenfeld²^*, Melitza Iglesias-Rodriguez¹^*, Jon P Fryzek²^* and Jun Su¹

¹Sanofi, Cambridge, MA
²EpidStrategies, Rockville, MD

1632

Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis

Samuel Rubinstein, MD¹, Ryan C. Lynch, MD², Aakash Desai, MD³, Catherine Stratton, MPH⁴^*, Alokkumar Jha, PhD⁵^*, Ziad Bakouny, MD, MSc⁶^*, Andrew Schmidt, MD⁶^*, R. Alejandro Sica, MD⁷, Divaya Bhutani, MD⁸, Dimpy P. Shah, MD, PhD⁹^*, Sarah A Wall, MD¹⁰, Gary H. Lyman, MD¹¹, Nicole M. Kuderer, MD, MSc¹², Matthias Weiss, MD, PhD¹³, Jeremy L. Warner, MD, MS¹⁴, Keith E. Stockerl-Goldstein, MD¹⁵, Ruben Mesa, MD¹⁶ and Michael A. Thompson, MD, PhD¹⁷

¹Division of Hematology, University of North Carolina-Chapel Hill, Chapel Hill, NC
²Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA
³Division of Hematology, Department of Medicine, MayoClinic, Rochester, MN
⁴Yale University, New Haven, CT
⁵Stanford University, Palo Alto, CA
⁶Dana-Farber Cancer Institute, Boston, MA
⁷Hematology/Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY
⁸Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Jersey City, NJ
⁹Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX
¹⁰Division of Hematology, The Ohio State University, Columbus, OH
¹¹Fred Hutchinson Cancer Research Center, Seattle, WA
¹²Advanced Cancer Research Group, Seattle, WA
¹³Thedacare, Appleton, WI
¹⁴Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN
¹⁵Division of Oncology, Washington University, Saint Louis, MO
¹⁶Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX
¹⁷Aurora Cancer Care, Aurora Research Institute, Advocate Aurora Health, Delafield, WI

1633

Risk of Hypertension in Hemophilia Patients with a History of Inhibitors

Anna Ter-Zakarian, MD¹, Richard Barnes, PhD, MPH²^*, Rebecca Kruse-Jarres, MD, MPH³^*, Doris Quon, MD, PhD⁴, Shannon Jackson, MD, FRCPC⁵, Linda Sun, MD⁵^* and Annette von Drygalski, MD, Pharm D^2,6

¹Department of Medicine, Division of Hematology/Oncology, University of California San Diego, Glendale, CA
²Department of Medicine, Division of Hematology/Oncology, University of California San Diego, San Diego, CA
³Bloodworks Northwest/Washington Center for Bleeding Disorders, University of Washington, Seattle, WA
⁴Los Angeles Orthopedic Hemophilia Treatment Center, Orthopedic Institute for Children, Los Angeles, CA
⁵Division of Hematology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
⁶Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA

1634

Predictors of Glucocorticoid Responsiveness in Multicentric Castleman’s Disease

Kazutoshi Ebisawa, MD¹^*, Arika Nukina Shimura, MD²^*, Akira Honda, MD, PhD³^*, Yosuke Masamoto, MD, PhD⁴, Fumio Nakahara, MD, PhD⁴^* and Mineo Kurokawa, MD, PhD^4,5

¹University of Tokyo, Bunkyo-Ku, TKY, Japan
²University of Tokyo, Bunkyo-Ku, TKY, JPN
³University of Tokyo, Bunkyoku, TKY, Japan
⁴Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
⁵Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, Tokyo, Japan

1635

The Impact of ABO Blood Group on Clinical Outcomes and Susceptibility in COVID-19: A Retrospective Population Study of 3305 Patients

Waleed Alduaij, PhD, MBBS^1,2, Sarah Al-Youha, MD PhD²^*, Ahmad Al-Serri, PhD³^*, Sulaiman Almazeedi, MD²^*, Mohannad Al-Haddad, MD²^*, Mohammad H Jamal, MD MEd^2,3^* and Salman Al-Sabah, MD MBA^2,3^*

¹Division of Hematology, University of British Columbia, Vancouver, BC, Canada
²COVID-19 Research Group, Jaber Al-Ahmad Al-Sabah Hospital, Kuwait, Kuwait
³Kuwait University, Kuwait, Kuwait

1636

Hematologic Characteristics of Surviving Versus Non-Surviving COVID-19 Patients in Critical Care Units: Inner-City Hospital Experience, Detroit, MI

Nino Balanchivadze, MD¹, Raef Fadel, MD²^*, Jawad Sheqwara, MD¹^* and Philip Kuriakose, MD¹

¹Division of Hematology and Oncology, Henry Ford Hospital/Wayne State University, Detroit, MI
²Department of Internal Medicine, Henry Ford Hospital/Wayne State University, Detroit, MI

1637

Clinical Course and Outcomes of Sickle Cell Disease Patients with COVID-19 at a New York Hospital

Anita Mazloom, MD, Neil Nimkar, MD, Sonal Paul, MD and Ayanna Baptiste, MBBS

NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY

1638

Patient Reported Outcomes Among Systemic Mastocytosis (SM) Patients in Routine Clinical Practice: Results from the TouchStone Survey

Ruben A. Mesa, MD, FACP¹, Erin M. Sullivan, PhD²^*, David Dubinski, MBA, BS²^*, Brittany Carroll, MBA³^*, Valerie M. Slee, RN, BSN⁴^*, Susan Jennings, PhD⁴^*, Celeste Finnerty, PhD⁴^*, Linda Bohannon, RN, BSN, MSM⁵^*, Susan Mathias, MPH⁶^* and Mariana Castells, MD, PhD⁷^*

¹Mays Cancer Center at UT Health San Antonio, San Antonio, TX
²Blueprint Medicines Corporation, Cambridge, MA
³Biopharma Catalyst Consulting, Cambridge, MA
⁴The Mast Cell Disease Society, Sterling, MA
⁵Cancer Support Community, Washington, DC
⁶Health Outcomes Solutions, Winter Park, FL
⁷Brigham and Women’s Hospital, Boston, MA

1639

Autosomal Recessive Spherocytosis: A Series of 5 Cases of Compound Heterozygous SPTA1 Mutations

Susan Kirk, PA-C¹^*, Katie Bergstrom, MGC²^*, Richard L Hurwitz, M.D.¹^*, Donald Mahoney, MD¹, Alison A. Bertuch, MD, PhD¹ and Jacquelyn M. Powers, MD, MSc¹

¹Texas Children's Hematology Center, Baylor College of Medicine, Department of Pediatrics, Section of Hematology/Oncology, Houston, TX
²Seattle Children's Hospital, Seattle, WA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

904.P1.54 904. Outcomes Research—Non-Malignant Conditions: Poster I